These templates can be used on talk pages to alert editors that consensus has been formed on certain points of interest related to all (or a subset of) COVID-19 articles. The major benefit of such templates is the avoidance of repeated discussions on contentious topics, especially from new or infrequent editors.
WikiProject COVID-19 aims to add to and build consensus for pages relating to COVID-19. They have so far discussed items listed below. Please discuss proposed improvements to them at the project talk page.
For infoboxes on the main articles of countries, use Wuhan, Hubei, China for the origin parameter. (March 2020)
"Social distancing" is generally preferred over "physical distancing". (April 2020, May 2020)
Page title
COVID-19 (full caps) is preferable in the body of all articles, and in the title of all articles/category pages/etc.(RM April 2020, including the main article itself, RM March 2021).
SARS-CoV-2 (exact capitalisation and punctuation) is the common name of the virus and should be used for the main article's title, as well as in the body of all articles, and in the title of all other articles/category pages/etc. (June 2022, overturning April 2020)
Map
There is no consensus about which color schemes to use, but they should be consistent within articles as much as possible. There is agreement that there should be six levels of shading, plus gray for areas with no instances or no data. (May 2020)
There is no consensus about whether the legend, the date, and other elements should appear in the map image itself. (May 2020)
For map legends, ranges should use fixed round numbers (as opposed to updating dynamically). There is no consensus on what base population to use for per capita maps. (May 2020)
To ensure you are viewing the current list, you may wish to purge this page.
There is no consensus on whether the lab leak theory is a "conspiracy theory" or a "minority scientific viewpoint". (RfC, February 2021)
There is consensus against defining "disease and pandemic origins" (broadly speaking) as a form of biomedical information for the purpose of WP:MEDRS. However, information that already fits into biomedical information remains classified as such, even if it relates to disease and pandemic origins (e.g. genome sequences, symptom descriptions, phylogenetic trees). (RfC, May 2021)
In multiple prior non-RFC discussions about manuscripts authored by Rossana Segreto and/or Yuri Deigin, editors have found the sources to be unreliable. Specifically, editors were not convinced by the credentials of the authors, and concerns were raised with the editorial oversight of the BioEssays "Problems & Paradigms" series. (Jan 2021, Jan 2021, Jan 2021, Feb 2021, June 2021, ...)
The March 2021 WHO report on the origins of SARS-CoV-2 should be referred to as the "WHO-convened report" or "WHO-convened study" on first usage in article prose, and may be abbreviated as "WHO report" or "WHO study" thereafter. (RfC, June 2021)
The scientific consensus (and the Frutos et al. sources ([1][2]) which support it), which dismisses the lab leak, should not be described as "based in part on Shi [Zhengli]'s emailed answers." (RfC, December 2021)
A note on WP:MEDRS: Per this Wikipedia policy, we must rely on the highest quality secondary sources and the recommendations of professional organizations and government bodies when determining the scientific consensus about medical treatments.
Ivermectin: The highest quality sources (1234) suggest Ivermectin is not an effective treatment for COVID-19. In all likelihood, ivermectin does not reduce all-cause mortality (moderate certainty) or improve quality of life (high certainty) when used to treat COVID-19 in the outpatient setting (4). Recommendations from relevant organizations can be summarized as: Evidence of efficacy for ivermectin is inconclusive. It should not be used outside of clinical trials. (May 2021, June 2021, June 2021, July 2021, July 2021) (WHO, FDA, IDSA, ASHP, CDC, NIH)
Chloroquine & hydroxychloroquine: The highest quality sources (1234) demonstrate that neither is effective for treating COVID-19. These analyses accounted for use both alone and in combination with azithromycin. Some data suggest their usage may worsen outcomes. Recommendations from relevant organizations can be summarized: Neither hydroxychloroquine nor chloroquine should be used, either alone or in combination with azithromycin, in inpatient or outpatient settings. (July 2020, Aug 2020, Sep 2020, May 2021) (WHO, FDA, IDSA, ASHP, NIH)
Ivmmeta.com, c19ivermectin.com, c19hcq.com, hcqmeta.com, trialsitenews.com, etc: These sites are not reliable. The authors are pseudonymous. The findings have not been subject to peer review. We must rely on expert opinion, which describes these sites as unreliable. From published criticisms (12345), it is clear that these analyses violate basic methodological norms which are known to cause spurious or false conclusions. These analyses include studies which have very small sample sizes, widely different dosages of treatment, open-label designs, different incompatible outcome measures, poor-quality control groups, and ad-hoc un-published trials which themselves did not undergo peer-review. (Dec 2020, Jan 2021, Feb 2021)